Mazdutide — compound monograph
Dual glucagon and GLP-1 receptor agonist (oxyntomodulin analogue). Approved. The Institute assesses 2 outcomes for this compound and grades the strongest at moderate certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Mazdutide
- Compound class
- Dual glucagon and GLP-1 receptor agonist (oxyntomodulin analogue)
- Assessment series
- Incretin receptor agonists
- Synonyms and codes
- LY3305677 · IBI362 · OXM analogue · mazdutide (INN)
- Route as evaluated
- Subcutaneous once weekly
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 2381089-83-2 (record disputed across sources)
- Molecular formula
- not published in full
- Average mass
- ≈4600 (approximate)
- Monoisotopic mass
- not published
- ATC classification
- not assigned
§1.3Sequence and structural notes
Oxyntomodulin is an endogenous proglucagon product with intrinsic dual glucagon and GLP-1 receptor activity. Mazdutide is an engineered long-acting analogue of that natural dual agonist rather than a de-novo chimera. Published CAS assignments for this compound are inconsistent between secondary sources and the Institute does not treat any single record as authoritative.
§1.4Assessment status
The Institute assesses Mazdutide across 2 indications and grades the strongest of them at moderate certainty. Holds a marketing authorisation for at least one indication in at least one jurisdiction.
Table 1. Assessed outcomes for Mazdutide, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Obesity and overweight in adults | −14.4 % body weight at 48 weeks with 6 mg in a Chinese phase 3 trial versus −0.3 % with placebo | Moderate | 3 |
| Type 2 diabetes mellitus | −1.8 % HbA1c at 24 weeks with 6 mg | Moderate | 2 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.